CD274 and non-small cell lung carcinoma: This study supports the use of dual immunotherapy as a highly effective first-line treatment for advanced NSCLC, offering a substantial improvement in OS and response duration compared to traditional chemotherapy, irrespective of the patient’s PD-L1 expression level [12].